<DOC>
	<DOCNO>NCT01096979</DOCNO>
	<brief_summary>This double-masked evaluation safety efficacy LIPO-102 reduction subcutaneous abdominal adiposity .</brief_summary>
	<brief_title>An Evaluation Safety Efficacy LIPO-102 Reduction Subcutaneous Abdominal Adiposity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<criteria>Male non pregnant female Good general health Sufficient abdominal fat injection Signed informed consent BMI great equal 18 less 28 kg/m2 History stable weight past 3 month Known hypersensitivity study drug Treatment investigational agent within 30 day first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Subcutaneous Adipose Tissue Reduction</keyword>
</DOC>